ES Rosenberg, V Dorabawila, D Easton… - The New England … - ncbi.nlm.nih.gov
Background Population-based data from the United States on the effectiveness of the three coronavirus disease 2019 (Covid-19) vaccines currently authorized by the Food and Drug …
ES Rosenberg, V Dorabawila, D Easton, UE Bauer… - 2021 - academia.edu
BACKGROUND Population-based data from the United States on the effectiveness of the three coronavirus disease 2019 (Covid-19) vaccines currently authorized by the Food and …
ES Rosenberg, V Dorabawila… - The New England …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Population-based data from the United States on the effectiveness of the three coronavirus disease 2019 (Covid-19) vaccines currently authorized by the Food and Drug …
Background: US population-based data on COVID-19 vaccine effectiveness (VE) for the 3 currently FDA-authorized products is limited. Whether declines in VE are due to waning …
ES Rosenberg, V Dorabawila, D Easton… - The New England …, 2021 - europepmc.org
Background Population-based data from the United States on the effectiveness of the three coronavirus disease 2019 (Covid-19) vaccines currently authorized by the Food and Drug …
COVID-19 Vaccine Effectiveness by Product and Timing in New York State Page 1 COVID-19 Vaccine Effectiveness by Product and Timing in New York State OCTOBER 22, 2021 Eli …
ES Rosenberg, V Dorabawila… - The New England …, 2022 - scholarship.miami.edu
The effectiveness of the BNT162b2, mRNA-1273, and Ad26. COV2. S vaccines was assessed from May through August 2021. Initial protection was high, but there was a modest …
ES Rosenberg, V Dorabawila, D Easton, UE Bauer… - 2022 - cabidigitallibrary.org
Background: Population-based data from the United States on the effectiveness of the three coronavirus disease 2019 (Covid-19) vaccines currently authorized by the Food and Drug …